Israel Englander Salarius Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.17 - $41.34 $29,956 - $7.28 Million	-176,217 Reduced 60.37%	115,683 $23,000
Q2 2022 Aug 15, 2022	BUY	$0.16 - $0.42 $43,483 - $114,144	271,772 Added 1350.22%	291,900 $61,000
Q1 2022 May 16, 2022	SELL	$0.34 - $0.54 $15,452 - $24,542	-45,449 Reduced 69.31%	20,128 $8,000
Q4 2021 Feb 14, 2022	BUY	$0.49 - $1.01 $2,987 - $6,157	6,097 Added 10.25%	65,577 $32,000
Q3 2021 Nov 15, 2021	BUY	$0.8 - $1.15 $20,793 - $29,890	25,992 Added 77.62%	59,480 $61,000
Q2 2021 Aug 16, 2021	BUY	$1.02 - $1.52 $4,909 - $7,315	4,813 Added 16.78%	33,488 $35,000
Q1 2021 May 17, 2021	BUY	$1.0 - $3.0 $8,273 - $24,819	8,273 Added 40.55%	28,675 $42,000
Q4 2020 Feb 16, 2021	SELL	$0.65 - $1.34 $4,394 - $9,059	-6,761 Reduced 24.89%	20,402 $19,000
Q3 2020 Nov 16, 2020	BUY	$0.77 - $1.52 $20,915 - $41,287	27,163 New	27,163 $23,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.25M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.